AstraZeneca’s Latest Study on Budesonide-Formoterol: Key Insights for Investors

AstraZeneca ((AZN)) announced an update on their ongoing clinical study.

Study Overview: AstraZeneca recently completed a clinical study titled ‘Establishment of a FeNO Cutoff Value for Evaluating the Response to Budesonide-formoterol in Patients With Chronic Cough Suggestive of Cough Variant Asthma.’ The study aimed to determine a FeNO cutoff value to predict the effectiveness of budesonide-formoterol treatment in patients with chronic cough, a condition indicative of cough variant asthma. This research is significant as it seeks to enhance treatment precision for patients with chronic cough symptoms.

Intervention/Treatment: The study tested the drug combination budesonide-formoterol, administered as Symbicort® 160/4.5 mcg, to evaluate its efficacy in reducing cough symptoms. This treatment is intended to alleviate chronic cough by targeting inflammation and airway constriction.

Study Design: This was a multicenter, prospective, single-arm study involving around 1,000 participants across 40 sites in China. The study followed a single-group intervention model without masking, focusing on determining the primary purpose of establishing a predictive cutoff value for treatment response.

Study Timeline: The study began on August 29, 2024, and was last updated on September 17, 2025. These dates are crucial as they mark the study’s progression and completion, providing a timeline for data analysis and potential publication of results.

Market Implications: The completion of this study could positively impact AstraZeneca’s stock performance by reinforcing its position in the respiratory treatment market. The findings may boost investor confidence, especially if the results demonstrate significant improvements in treatment outcomes. Competitors in the respiratory drug market will likely monitor these developments closely.

The study is completed, and further details are available on the ClinicalTrials portal.